Encompass Health: Strong Performance and Strategic Expansion Drive Buy Rating

William Blair analyst Ryan Daniels has maintained their bullish stance on EHC stock, giving a Buy rating on April 25.

Ryan Daniels has given his Buy rating due to a combination of factors that highlight Encompass Health’s strong performance and promising future outlook. The company reported impressive first-quarter results, with revenue and adjusted EBITDA surpassing expectations, leading to a positive market reaction. Management’s decision to raise guidance across key financial metrics further underscores confidence in sustained growth.
Encompass Health’s robust volume trends, particularly in same-store discharge growth and record-high occupancy rates, contribute to the positive outlook. Additionally, the company has managed labor costs effectively, with improvements in turnover metrics and a reduction in premium labor expenses. The strategic expansion plans to increase bed capacity in response to strong demand also support the Buy rating, indicating potential for continued growth in the coming years.

According to TipRanks, Daniels is a 4-star analyst with an average return of 6.8% and a 46.79% success rate. Daniels covers the Healthcare sector, focusing on stocks such as Encompass Health, Health Catalyst, and HealthStream.

In another report released on April 25, KeyBanc also maintained a Buy rating on the stock with a $122.00 price target.